Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report

A A Pract. 2022 Aug 1;16(8):e01604. doi: 10.1213/XAA.0000000000001604.

Abstract

The use of mechanical circulatory support (MCS) devices continues to expand in cases of refractory cardiogenic shock. Bleeding is one of the most common complications associated with MCS, and management can be challenging due to need for systemic anticoagulation. Significant hemoptysis can be a devastating complication. We describe a case of a patient supported by a right ventricular assist device with an oxygenator and a left ventricular assist device who developed pulmonary hemorrhage that was successfully treated with nebulized tranexamic acid (TXA). Following a 5-day treatment course, bleeding resolved, no adverse side effects were noted, and systemic anticoagulation was resumed.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants
  • Heart-Assist Devices* / adverse effects
  • Hemoptysis / complications
  • Hemoptysis / drug therapy
  • Hemorrhage / complications
  • Humans
  • Shock, Cardiogenic / drug therapy
  • Shock, Cardiogenic / etiology
  • Tranexamic Acid* / therapeutic use

Substances

  • Anticoagulants
  • Tranexamic Acid